Open AccessProtein-based nanoplatform for detection of tumorigenic polyps in the colon via noninvasive mucosal routes
Author(s) -
ChunChieh Chen,
Mo Baikoghli,
R. Holland Cheng
Publication year - 2021
Publication title -
pharmaceutical patent analyst
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.247
H-Index - 15
eISSN - 2046-8962
pISSN - 2046-8954
DOI - 10.4155/ppa-2020-0034
Subject(s) - nanomedicine , bioavailability , chemistry , colorectal cancer , heterologous , nanoparticle , nanocapsules , nanotechnology , cancer research , medicine , pharmacology , cancer , materials science , biochemistry , gene
The use of nanoparticulate systems to diagnose and treat tumors has gained momentum with the rapid development of nanomedicine. Many nanotheranostics fail due to insufficient bioavailability and low accumulation at the tumor site, resulting in undesirable side effects. We describe the use of an engineered hepatitis E viral nanoparticle (HEVNP) with enhanced bioavailability, tissue retention and mucosal penetration capacities. HEVNP is a modular nanocapsule that can encapsulate heterologous nucleotides, proteins and inorganic metals, such as ferrite oxide nanoparticles. Additionally, the exterior protruding arms of HEVNP is composed of loops that are used for chemical coupling of targeting and therapeutic peptides. We propose the use of HEVNP to target colorectal cancer (i.e., polyps) with imaging-guided delivery using colonoscopy.